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Abstract
Background: Clinical analgesic trials typically report response as group mean results. However, research has shown
that few patients are average and most have responses at the extremes. Moreover, group mean results do not
convey response levels and thus have limited value in representing the benefit-risk at an individual level.
Responder analyses and numbers-needed-to-treat (NNT) are considered more relevant for evaluating treatment
response. We evaluated levels of analgesic response and Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) score improvement and the associated NNTs.
Methods: This was a post-hoc analysis of a 6-week, randomized, double-blind study (N = 387) comparing etoricoxib 90
mg, etoricoxib 120 mg, naproxen 1000 mg, and placebo in AS. Spine pain and BASDAI were measured on a 100-mm
visual analog scale. The number and percentage of patients achieving ≥30% and ≥50% improvement in both BASDAI
and spine pain were calculated and used to determine the corresponding NNTs. Patients who discontinued from the
study for any reason were assigned zero improvement beyond 7 days of the time of discontinuation.
Results: For etoricoxib 90 mg, etoricoxib 120 mg and naproxen 1000 mg, the NNTs at 6 weeks compared with placebo
were 2.0, 2.0, and 2.7 respectively for BASDAI ≥30% improvement, and 3.2, 2.8, and 4.1 for ≥50% improvement. For spine
pain, the NNTs were 1.9, 2.0, and 3.2, respectively, for ≥30% improvement, and 2.7, 2.5, and 3.7 for ≥50% improvement. The
differences between etoricoxib and naproxen exceeded the limit of ±0.5 units described as a clinically meaningful
difference for pain. Response rates and NNTs were generally similar and stable over 2, 4, and 6 weeks.
Conclusions: For every 2 patients treated with etoricoxib, 1 achieved a clinically meaningful (≥30%) improvement
in spine pain and BASDAI beyond that expected from placebo, whereas the corresponding values were
approximately 1 in every 3 patients treated with naproxen. Use of NNTs and responder analyses provide additional,
complementary information beyond population mean responses when assessing efficacy compared to placebo
and amongst active therapies.
Background
Clinical trials of analgesic medications in ankylosing
spondylitis (AS) and other disease states typically report
response as group mean results. However, research has
shown that few patients are average and most have
analgesic responses at the extremes [1-4]. For example,
we have previously shown that in chronic low back
pain, patient assessment of response to treatment has
more of a U-shaped curve rather than a bell-shaped
curve [4]. While it is implied that the group mean is
applicable to most patients, it actually applies to few
patients. Moreover, by assuming a bell-shaped curve for
responders, group means imply ranges and distributions
for responses that are not correct when viewed from the
perspective of individual patient responses, and therefore * Correspondence: paul_peloso@merck.com
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expectations with patients.
Am o r ep r a c t i c a lm e a s u r et oe s t i m a t er e s p o n s ei sa n
individual patient responder analysis, which calculates
the distribution of the magnitude of responses across
individual patients, as has been done for osteoarthritis
[5] and fibromyalgia [6]. Such an approach provides the
proportion of patients achieving specified response
levels, and thus adds the additional dimension of a clini-
cally important change in patient response expected of a
given therapy. Since adverse events are typically pre-
sented as rates, use of responder analyses puts both ben-
efit and risk on the same metric and further facilitates
benefit-risk discussions with individual patients and can
help clinicians make more informed decisions.
The numbers-needed-to-treat (NNT) approach allows
a comparison to placebo in a single number, and con-
veys additional information about expected treatment
benefits, beyond that expected for with placebo in a
straightforward manner. It has been suggested that a dif-
ference of ± 0.5 NNT units is a clinically meaningful
difference [7-10].
The Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT) group sug-
gested that responder analyses in pain should be based
on established thresholds of change considered to be
important [7]. Specifically, they suggest that the minimal
clinically important difference in improvement is a 10-
20% decrease on a 0-to-10 numerical rating scale,
whereas improvements of ≥30% and ≥50% represent
moderately important and substantial improvements [7].
An additional improvement of ≥70% is considered
“extensive” [4-6]. Similarly, it has been demonstrated
that the minimal clinically important difference in the
Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI), an outcome measure specific to AS, has been
reported to be a 22% improvement [11]. Thus changes
of 30%, 50% and 70% on the BASDAI are of certain
clinical benefit.
The purpose of this post-hoc analysis was to evaluate
the proportions of patients achieving improvements
from baseline in BASDAI and spine pain of 15%, 30%,
50%, and 70% and their associated NNTs over time in a
study of etoricoxib, naproxen, and placebo in AS [12].
Specifically, we sought to describe the influence of var-
ious time points as well as various thresholds of
response, on the responder proportions and associated
NNTs, in an AS population.
Methods
Study design and patients
The methods of the trial have been previously published
in detail [12]. Briefly, this was a double-blind, parallel-
group, 52-week active-comparator and placebo-
controlled study comparing etoricoxib 90 mg, etoricoxib
120 mg, and naproxen 1000 mg. The study consisted of
a 6-week placebo-controlled period (Part I), and an
optional 46-week, active-comparator period (Part II).
Patients who received placebo in Part I were assigned to
one of the 3 active treatment groups in equal ratios.
Patients who received active treatment in Part I
remained on that treatment for Part II. The original
published study on which this secondary analysis is
based was conducted in accordance with the standards
established by the Declaration of Helsinki. For each
study site, the protocol and consent form were approved
by an institutional review board committee or ethics
review committee. All patients provided written
informed consent before enrollment.
Patients were ≥18 years of age, had a diagnosis of AS
based on the modified New York criteria for AS [13] ≥6
months prior to study start, a history of therapeutic
benefit with nonsteroidal anti-inflammatory drugs
(NSAIDs), and routine NSAID use at a therapeutic dose
level for ≥30 days prior to enrollment. Patients were
also required to have used approved nonstudy antirheu-
matic therapy (e.g., methotrexate, sulfasalazine) at stable
dose. After washout of prestudy NSAIDs, patients had
to demonstrate a worsening of spine pain of ≥40 mm
on a 100-mm visual analog scale (VAS), and an increase
of ≥30% (minimum 12 mm) compared with the rating
at the screening visit. Pertinent exclusion criteria
included concurrent rheumatic disease (e.g., systemic
lupus erythematosus, gout), but patients with chronic
peripheral arthritis were eligible if spine pain was the
primary source of pain. Excluded medications included
corticosteroids within 1 month of screening, or analge-
sics within 3 days of study entry and throughout the
study. Low-dose aspirin (≤100 mg once daily) was per-
mitted for cardiovascular prophylaxis, and acetamino-
phen was available for rescue analgesia.
Clinical assessments were performed at screening,
flare/randomization, and at weeks 2, 4, 6, 8, 16, 26, 43,
and 52, and/or at the discontinuation visit. The co-pri-
mary endpoints of the original study were the patient
assessment of spinal pain (100-mm VAS), patient global
assessment of disease activity (100-mm VAS), and the
Bath Ankylosing Spondylitis Functional Index (100-mm
VAS). Secondary endpoints included patient global
assessment of response to therapy (PGART; 0 = excel-
lent to 4 = no response) and BASDAI (100-mm VAS).
Responder analysis
The present responder analysis was limited to the initial
6-week placebo-controlled portion of the trial, and fol-
lowed principles from IMMPACT [7] and ACTINPAIN
[14] regarding outcomes, imputation methods, and evi-
dence quality. The placebo portion of the trial was
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tions of denying AS patients in pain access to effective
therapy.
The PGART is a straightforward assessment of
response, on a simple 5-point scale. For each treatment
arm we calculated the number and percentage patients
at each PGART level at Week 6. For both BASDAI and
s p i n ep a i n ,t h en u m b e ra n dp e r c e n t a g eo fp a t i e n t s
achieving ≥15%, ≥30%, ≥50%, and ≥70% improvement
from baseline were calculated at Weeks 2, 4, and 6 and
these values were used to determine the corresponding
NNTs. Patients who discontinued from the study for
any reason were assigned zero improvement beyond 7
days from the time of discontinuation.
Since this exploratory analysis was descriptive in nat-
ure, no formal statistical hypothesis testing was per-
formed, nor was adjustment made for multiplicity.
Results
Patients
Baseline patient characteristics are shown in Table 1.
Most patients were male, had a mean age of 44 years, a
mean baseline spine pain of 77 mm, and a mean BAS-
DAI score of 55 mm.
PGART
As shown in Figure 1, the distribution of PGART
responses at 6 weeks for the individual treatment groups
does not show a normal, Gaussian distribution
Responders
Predictably, for both BASDAI (Figure 2) and spine pain
(Figure 3), a greater proportion of patients achieved a
1 5 %i m p r o v e m e n tf r o mb a s e l i n et h a na7 0 %i m p r o v e -
ment from baseline with active drug and placebo. The
proportions of patients achieving various thresholds of
response were generally stable over Weeks 2 through 6
for patients receiving active treatment. Response with
placebo was highly dependent on the level of response
examined, falling at six weeks from about 30% to 5%
or below for both outcomes. There was also a ten-
dency for placebo response rates to fall over the 2-6
week time frame. For all thresholds of response, sub-
stantially more patients receiving active treatment
achieved a given threshold compared to those receiving
placebo, and in most cases, numerically more patients
receiving etoricoxib 90 mg or 120 mg achieved a given
level of response compared to those receiving
naproxen 1000 mg.
Numbers-Needed-to-Treat
Consistent with the results for the percentages of respon-
ders, NNTs were higher (i.e., worse) when higher thresh-
olds of response were required for both BASDAI (Figure
4) and spine pain (Figure 5). NNTs generally decreased
(i.e., improved) slightly over time, and in all cases were
lower (i.e., better) with etoricoxib than with naproxen for
both BASDAI (Figure 4) and spine pain (Figure 5). For
the outcome of ≥30% improvement, NNTs compared
Table 1 Baseline patient characteristics
Placebo
N=9 3
Etoricoxib 90 mg
N = 103
Etoricoxib 120 mg
N=9 2
Naproxen 1000 mg
N=9 9
Age (years), mean (SD) 43.7 (12.1) 43.1 (12.1) 42.5 (12.0) 45.0 (11.4)
Female (%) 20.4 26.2 21.7 20.2
History of iritis (%) 33.3 37.9 31.5 31.3
History of chronic peripheral arthritis (%) 39.8 39.8 39.1 41.4
History of corticosteroid use (%) 32.3 23.3 23.9 22.2
Concomitant DMARD use (%)* 19.4 26.2 19.6 23.2
Baseline BASDAI (100-mm VAS), mean (SD) 54.1 (27.0) 56.9 (22.5) 55.2 (25.1) 54.1 (23.2)
Baseline spine pain (100-mm VAS), mean (SD) 77.2 (15.2) 78.0 (13.9) 78.0 (14.2) 77.2 (16.5)
*Auranofin, azathioprine, cyclosporine, leflunomide, methotrexate, methotrexate sodium, or sulfasalazine
DMARD: disease-modifying antirheumatic drug; SD: standard deviation; VAS: visual analog scale
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Figure 1 Distribution of PGART response at 6 weeks.
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Page 3 of 8with placebo at 6 weeks were 2.0 or lower for etoricoxib
90 mg or 120 mg, and 2.7 or higher with naproxen 1000
mg with both outcomes. For the outcome of ≥50%
improvement, NNTs compared with placebo at 6 weeks
w e r e3 . 2o rl o w e rf o re t o r i c o x i b9 0m go r1 2 0m g ,a n d
3.7 or higher with naproxen 1000 mg.
In most cases for both spine pain and BASDAI score,
the NNTs for etoricoxib were at least 0.5 units below
those for naproxen, suggesting a clinically relevant dif-
ference favoring etoricoxib.
Discussion
The purpose of this study was to perform a responder
analysis and calculate the associated NNTs to examine
the influence of response thresholds and the time point
chosen for analysis, in a trial comparing etoricoxib,
naproxen, and placebo in AS [12]. It was demonstrated
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Figure 2 Proportions of patients achieving various thresholds
of improvement in BASDAI from baseline at (A) 2 weeks, (B), 4
weeks, and (C) 6 weeks.
Etoricoxib 90 mg Etoricoxib 120 mg Naproxen 1000 mg  Placebo
A.
15% 30%  50%  70%
15% 30%  50%  70%
15% 30%  50%  70%
B.
C.
88
78
56
35
89
77
57
40
82
65
45
27
44
34
16
8
0
20
40
60
80
100
Improvement from baseline
2 weeks
4 weeks
6 weeks
P
e
r
c
e
n
t
a
g
e
 
o
f
 
p
a
t
i
e
n
t
s
84
74
54
38
81
77
60
41
70
62
47
32
38
30
16
8
0
20
40
60
80
100
Improvement from baseline
P
e
r
c
e
n
t
a
g
e
 
o
f
 
p
a
t
i
e
n
t
s
82
76
52
38
82
73
55
39
70
54
42
28
33
23
15
6
0
20
40
60
80
100
Improvement from baseline
P
e
r
c
e
n
t
a
g
e
 
o
f
 
p
a
t
i
e
n
t
s
Figure 3 Proportions of patients achieving various thresholds
of improvement in spine pain from baseline at (A) 2 weeks, (B)
4 weeks, and (C) 6 weeks.
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Page 4 of 8that response on the PGART does not follow a normal
distribution in AS, but rather, has a highly skewed dis-
tribution. These results suggest that group mean results
should not be inferred to represent a normal distribu-
tion of responses. The implication in the present analy-
sis suggests that group mean results do not reflect
responses that patients might expect to achieve, consis-
tent with previous research in other pain states [1-6].
The primary report of this trial showed average
improvement in BASDAI at 6 weeks of approximately
50% for the etoricoxib groups and 44% for the naproxen
group. By examining the percentage of patients achieving
various levels of improvements ranging from 15 to 70%,
we found that at week 6, 70% of patients receiving etori-
coxib and 57% of patients receiving naproxen experi-
enced moderate improvement (≥30%) in BASDAI, and
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Figure 4 NNTs vs. placebo for various thresholds of
improvement in BASDAI from baseline at (A) 2 weeks, (B) 4
weeks, and (C) 6 weeks.
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Figure 5 NNTs vs. placebo for various thresholds of
improvement in spine pain from baseline at (A) 2 weeks, (B) 4
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Page 5 of 8that approximately 48% and 38% experienced substantial
improvement (≥50%), with 30% and 20% experiencing
extensive (≥70%) improvement. Further, the percentages
for spine pain response were generally similar. This pro-
vides a very different picture of response than mean
changes, and would seem more relevant in communicat-
ing treatment expectations with patients. Consistent with
the original report and the group mean analysis, substan-
tially more patients receiving etoricoxib or naproxen
achieved various thresholds of response for both BASDAI
and spine pain than did patients receiving placebo, where
active treatments were significantly more effective than
placebo for both measures (p < 0.001) [12].
The percentages of responders at 6 weeks for a given
threshold were numerically higher for etoricoxib than
naproxen, by about 10% for both BASDAI and spine
pain. These differences favoring etoricoxib are reflected
in the lower (better) NNTs with etoricoxib: after 6
weeks, approximately 1 in 2 patients receiving etoricoxib
will achieve a 30% improvement beyond that seen with
placebo, 1 in 3 will achieve a 50% improvement, and 1
in 4 will achieve a 70% improvement. By contrast, the
corresponding values for naproxen are approximately 1
in 3, 1 in 4, and 1 in 6, respectively.
Although a difference of 1 or 2 NNT units may not
appear to be consequential, a difference of ± 0.5 NNT
units has been previously cited as a meaningful differ-
ence [7,15]. Such meaningful differences in NNTs
between etoricoxib and naproxen are consistent with
the results from the main analysis, in which changes
from baseline in BASDAI and spine pain were signifi-
cantly greater with etoricoxib than naproxen (p < 0.05)
[12].
Some important patterns emerged. As noted, the per-
centages of responders in the active treatment groups
were generally stable over time, whereas the percentages
of responders in the placebo group tended to decrease
over time. This likely reflects the extent and duration
that placebo can exert a positive effect in a highly
inflammatory condition. This observation likely accounts
for the decreasing (improving) NNTs for active treat-
ment over time despite the generally stable percentages
of responders. This is interesting, and confirms that
effective therapies generate stable, low NNTs in AS, as
has been demonstrated in osteoarthritis [5]. Where
therapies are less efficacious, NNTs can increase sub-
stantially with duration of observation, as has been seen
with ibuprofen in osteoarthritis [5], and with pregabalin
in fibromyalgia [6].
NNTs in the range 2-3 at ≥30% improvement and 3-4
at ≥50% improvement for etoricoxib and naproxen for
AS were much lower than the NNT of 7 seen for etori-
coxib 60 mg or 90 mg after 12 weeks about in chronic
low back pain [4], and 4-5 for etoricoxib 30 mg or 60
mg or naproxen 1000 mg in osteoarthritis after 12
weeks [5]. In acute postoperative pain, the NNT for
≥50% pain relief over 6 hours was 1.9 compared with
placebo [16]. This speaks to the variability of response
to both placebo and etoricoxib across various acute and
chronic pain conditions.
Group mean results are usually a mandatory require-
ment for regulatory approvals and, despite the limita-
tions described here, are valuable in demonstrating that
a therapy works in general. In addition, statistics using
group means are the most efficient clinical trial designs
relative to a comparison of proportions. Further, group
mean responses are often used by clinicians to make
cross-study comparisons among agents, which is often
necessary since this is the most common method of
reporting in the literature. However, mm-based mea-
surements of population means is likely to be a fairly
abstract concept to most patients, and does not inform
the individual’s likelihood of response. On the other
hand, NNTs are more straightforward to understand
and likely more easily conveyed to patients. NNTs alone
do not present a full efficacy profile, in the same way
that group mean results also do not present a full pro-
file, and it would be beneficial to include both types of
results in studies to allow a more complete efficacy pro-
file for clinicians accessing the literature. These NNTs
have been calculated using outcomes regarded as impor-
tant both by clinicians [7]and patients [17].
There are two other important aspects to this analysis.
First, we looked at response at various timepoints and
found that both the percentages of responders in the
active treatment groups and the related NNTs were rea-
sonably stable over time, consistent with previous
research showing that early response to coxibs is highly
predictive of later response [18]. Therefore, clinicians
can not only inform their patients as to the degree of
response that can be expected, but also the time frame
for such responses. Second, we assigned patient discon-
tinuations 0% improvement from the point of dropout
forward through the remainder of the study [19]. By
contrast, analyses often use the “last observation carried
forward” (LOCF) approach, which can lead to an
inflated efficacy result. For example, a patient who
experienced good efficacy but who discontinued after
week 2 because of an adverse experience would have his
or her favorable efficacy score carried forward for
another 4 weeks despite not receiving treatment during
that time. Our more conservative approach of assigning
such patients as nonresponders from that point onward
is a more accurate assessment of efficacy and tolerabil-
ity, and more representative of real-world benefit/risk.
The main limitation of this analysis is that it was post-
hoc, although we did use established definitions for
meaningful response [7]. Because of its descriptive
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results should be viewed as hypothesis-generating.
These findings are nonetheless consistent with the pri-
mary analysis, with respect to the relative efficacies of
etoricoxib, naproxen, and placebo [12]. Since this was
an analysis of a single AS trial of just 6 weeks’ duration,
and with smaller patient numbers compared with
responder analyses meta-analyses [5,6] even though
there were comparable to numbers studies in CLBP [4],
these results should be replicated in other AS datasets.
Whether the results demonstrated for etoricoxib and
naproxen can be extrapolated to other NSAIDs or to
other analgesics used to treat AS, or whether these
results apply beyond the 6 week timepoint of the analy-
sis cannot be addressed in this dataset, and remains
unknown. However, we note that Dougados and collea-
gues found that the percentage of responders to piroxi-
cam and meloxicam in AS was similar at 6 weeks and 1
year [20], and Reginster and colleagues found that
response to etoricoxib and naproxen had similar efficacy
in OA through 138 weeks, suggesting response to
NSAIDs is fairly stable [21]. Interestingly, however, in
an analysis of data from 7 OA trials, Moore and collea-
gues found that both the percentages of responders and
NNTs were generally stable over 12 weeks for etori-
coxib, celecoxib and naproxen, but were relatively
unstable for ibuprofen, particular for the NNTs, which
increased (worsened) by as much as nearly 200% [5].
Conclusions
In conclusion, we found that individual patient response
is not normally distributed, and rather tends to fall
toward the extremes, and as such is not accurately
represented by group mean responses. Group mean data
are important for understanding that a drug is clearly
superior to placebo, but are less valuable for informing
patients of expected responses. Responder analyses and
NNTs should be presented alongside group mean clini-
cal trial results as they provide a complementary view of
efficacy data facilitate doctor-patient discussions of
expected benefits, and are more clinically relevant.
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